Medicus Pharma grants director options for 25,000 shares

Medicus Pharma Ltd. reported that director Robert J. Ciaruffoli received a stock option grant on December 16, 2025.

Rhea-AI Filing Summary

Medicus Pharma Ltd. reported that director Robert J. Ciaruffoli received a stock option grant on December 16, 2025. The option gives him the right to buy 25,000 common shares at an exercise price of $1.8 per share and was granted at no upfront cost.

The option is scheduled to vest quarterly in four equal installments over one year and expires on December 16, 2030. After this grant, he beneficially owns 25,000 stock options, held directly.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Ciaruffoli Robert J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Medicus Pharma (MDCX) disclose in this report?

Medicus Pharma disclosed that a director received a stock option grant for 25,000 common shares with an exercise price of $1.8 per share on December 16, 2025.

Who received the stock option grant at Medicus Pharma (MDCX)?

The stock option grant was reported by director Robert J. Ciaruffoli, as indicated by the signature line naming him as the reporting person.

What are the vesting terms of the Medicus Pharma (MDCX) director stock options?

The option is scheduled to vest quarterly in four equal installments over one year, according to the explanation of responses.

What is the exercise price and expiration date of the Medicus Pharma (MDCX) option grant?

The option has an exercise price of $1.8 per share and an expiration date of December 16, 2030.

How many shares underlie the Medicus Pharma (MDCX) director option grant?

The stock option covers 25,000 common shares of Medicus Pharma Ltd., as shown in the derivative securities table.

How many derivative securities does the Medicus Pharma (MDCX) director hold after this grant?

Following the reported transaction, the director beneficially owns 25,000 stock options, held with direct ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/18/2025 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ciaruffoli Robert J.

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PA 19428

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.8	12/16/2025		A		25,000		(1)	12/16/2030	Common Shares	25,000	$0	25,000	D

Explanation of Responses:

1. The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Robert J. Ciaruffoli	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.